FDA Approves CREXONT — Amneal Pharmaceuticals LLC

# FDA Approves Amneal Pharmaceuticals' CREXONT for Parkinson's Disease Treatment Amneal Pharmaceuticals LLC received FDA approval for CREXONT (carbidopa and levodopa), an oral formulation of the longstanding Parkinson's disease therapeutic combination, positioning the company to capture market share in the competitive carbidopa-levodopa segment currently dominated by established branded and generic competitors. The approval expands Amneal's neurology portfolio and provides prescribers with an additional treatment option in a market where patient demand remains steady due to Parkinson's disease's chronic and